ArticleFrontiers of medicine2024

The novel anthraquinone compound Kanglexin prevents endothelial-to-mesenchymal transition in atherosclerosis by activating FGFR1 and suppressing integrin β1/TGFβ signaling.

Yixiu Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.